Autoimmune thyroid disease (AITD) stands as the most frequent organ-specific illness affecting the thyroid gland [3]. It occurs when the body's immune system mistakenly targets its own thyroid tissue, leading to a breakdown in immune tolerance [4, 7]. This complex process involves a combination of genetic, environmental, and epigenetic factors that trigger the activation of autoreactive B and T lymphocytes [3, 4, 5]. Ultimately, these immune reactions disrupt normal thyroid function, manifesting in two primary clinical presentations: an overproduction or a decline of vital thyroid hormones [3].
The condition generally splits into two main phenotypes, each characterized by distinct underlying mechanisms and autoantibody profiles [5]. Recognizing these forms helps clinicians understand the wide array of physical signs patients experience:
- Hashimoto's Thyroiditis (HT): This form is typically marked by the presence of thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies, along with a gradual infiltration of lymphocytes into the thyroid gland [3]. Over time, this progressive cellular destruction can lead to subclinical or overt hypothyroidism, where the gland underproduces hormones [3].
- Graves' Disease (GD): In contrast, this presentation features stimulatory autoantibodies directed against the TSH receptor [3, 5]. This abnormal stimulation drives the gland to overproduce hormones, resulting in hyperthyroidism [3].
Because thyroid hormones regulate metabolism across the entire body, the physical manifestations of AITD vary widely depending on whether hormone levels are too high or too low. Patients with Hashimoto's thyroiditis often experience symptoms related to a sluggish metabolism, while those with Graves' disease may notice signs of an accelerated system, such as rapid heartbeat, unintended weight loss, and anxiety. Furthermore, Graves' disease can involve extrathyroidal manifestations like Graves' eye disease, which affects orbital soft tissues, causing eyelid retraction, inflammation, and sometimes vision complications [7].
Diagnosing autoimmune thyroid disease involves evaluating clinical presentations alongside specific laboratory markers. Clinicians look for the presence of thyroid-specific autoantibodies, such as anti-TPO, anti-TG, and TSH receptor antibodies, which confirm the autoimmune nature of the dysfunction [2, 3, 5]. Blood tests measuring thyroid hormones and TSH help determine whether the gland is underactive or overactive [3, 6]. Because AITD can sometimes coexist with other conditions—such as latent primary adrenal insufficiency, vitiligo, or Sjögren's syndrome—comprehensive diagnostic evaluations are sometimes necessary when patients present with overlapping or recurrent nonspecific symptoms like persistent fatigue [1, 2, 6].
Sources
- [1] Comorbid Latent Adrenal Insufficiency with Autoimmune Thyroid Disease
- [2] Correlation between autoimmune thyroid disease and vitiligo: An analytical study
- [3] Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment
- [4] Activation of thyroid antigen-reactive B cells in recent onset autoimmune thyroid disease patients
- [5] Molecular Mechanisms in Autoimmune Thyroid Disease
- [6] Autoimmune Thyroid Disease in Primary Sjögren's Syndrome: Real-life Screening Practice and Clinical Outcomes
- [7] Extrathyroidal Manifestations of Thyroid Disease: Graves Eye Disease
- [8] Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes